Teva Takes FDA To Court In Challenge To “Authorized” Generics

The generic firm sues FDA, asserting the agency exceeded its expertise in finding that the marketing of “brand generics” during a first-filer’s 180-day exclusivity period promotes competition. Teva’s lawsuit in D.C. federal court comes two weeks after Mylan filed a separate, but similar, action against FDA in West Virginia.